Patents by Inventor Bernd Bohrmann
Bernd Bohrmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200223912Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.Type: ApplicationFiled: September 9, 2019Publication date: July 16, 2020Inventors: Fiona Grueninger, Guy Georges, Olaf Mundigl, Michael Schraeml, Bernd Bohrmann, Ulrich Goepfert, Joerg Benz, Hubert Kettenberger
-
Patent number: 10465000Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.Type: GrantFiled: December 22, 2016Date of Patent: November 5, 2019Assignee: HOFFMANN-LA ROCHE INC.Inventors: Fiona Grueninger, Guy Georges, Olaf Mundigl, Michael Schraeml, Bernd Bohrmann, Ulrich Goepfert, Joerg Benz, Hubert Kettenberger
-
Publication number: 20190276530Abstract: The present invention relates to blood brain barrier shuttles that bind receptors on the blood brain barrier (R/BBB) and methods of using the same.Type: ApplicationFiled: December 19, 2018Publication date: September 12, 2019Applicant: Hoffmann-La Roche Inc.Inventors: Bernd Bohrmann, Per-Ola Freskgard, Peter Maier, Jens Niewoehner, Alain Tissot-Daguette, Eduard Urich
-
Patent number: 10308710Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.Type: GrantFiled: December 22, 2016Date of Patent: June 4, 2019Assignee: HOFFMANN-LA ROCHE INC.Inventors: Fiona Grueninger, Guy Georges, Olaf Mundigl, Michael Schraeml, Bernd Bohrmann, Ulrich Goepfert, Joerg Benz, Hubert Kettenberger
-
Publication number: 20170174776Abstract: Herein is reported a fusion polypeptide comprising i) at least one binding site, e.g. which comprises an antibody heavy chain variable domain and an antibody light chain variable domain, and which binds to an internalizing cell surface receptor, and ii) at least one pharmaceutically active compound, whereby the EC50-value of the binding pair that binds to an internalizing cell surface receptor determined at pH 5.5 is higher than the EC50-value of the same binding pair determined at pH 7.4 and its use for delivering a pharmaceutically active compound across the blood-brain-barrier.Type: ApplicationFiled: December 1, 2015Publication date: June 22, 2017Applicant: Roche Glycart AGInventors: Bernd Bohrmann, Per-Ola Freskgard, Adrian Hugenmatter, Erhard Kopetzki, Ekkehard Moessner, Jens Niewoehner, Hadassah Sumum Sade, Pablo Umaña
-
Publication number: 20170129949Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.Type: ApplicationFiled: December 22, 2016Publication date: May 11, 2017Inventors: Fiona Grueninger, Guy Georges, Olaf Mundigl, Michael Schraeml, Bernd Bohrmann, Ulrich Goepfert, Joerg Benz, Hubert Kettenberger
-
Patent number: 9562091Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.Type: GrantFiled: December 18, 2014Date of Patent: February 7, 2017Assignee: Hoffmann-La Roche Inc.Inventors: Fiona Grueninger, Guy Georges, Olaf Mundigl, Michael Schraeml, Bernd Bohrmann, Ulrich Goepfert, Joerg Benz, Hubert Kettenberger
-
Publication number: 20160168253Abstract: The invention relates to a fusion protein comprising an antibody directed to A?, a monovalent binding entity which binds to a blood brain barrier receptor and a neprilysin.Type: ApplicationFiled: July 30, 2014Publication date: June 16, 2016Applicant: Hoffmann- La Roche Inc.Inventors: Bernd Bohrmann, Per-Ola Freskgard, Hendrik Knoetgen, Jens Niewoehner
-
Patent number: 9290567Abstract: An antibody binding to Tau that is phosphorylated at serine 422 (pS422), which specifically binds to phosphorylated Tau fragment of SEQ ID NO:9 and to Tau pS422, but does not bind to Tau and to phosphorylated MCAK fragment of SEQ ID NO:17. The antibody is useful in the treatment of a Tauopathy.Type: GrantFiled: June 6, 2013Date of Patent: March 22, 2016Assignee: Hoffmann-La Roche Inc.Inventors: Bernd Bohrmann, Ulrich Goepfert, Fiona Grueninger, Walter Huber, Hans-Willi Krell, Valeria Lifke, Olaf Mundigl, Sonja Offner, Laurence Ozmen, Michael Schraemi
-
Patent number: 9272031Abstract: The present invention relates to a purified antibody molecule preparation being characterized in that at least one antigen binding site comprises a glycosylated asparagine (Asn) in the variable region of the heavy chain (VH). More specifically, a pharmaceutical and a diagnostic composition comprising said antibody molecule and antibody mixtures are provided which is/are capable of specifically recognizing the ?-A4 peptide/A?4. The present invention relates in particular to a mixture of antibodies comprising one or two glycosylated antigen binding sites with a glycosylated asparagine (Asn) in the variable region of the heavy chain, i.e. mixtures of isoforms of antibodies which comprise a glycosylated Asn in the variable region of the heavy chain (VH). Also disclosed are compositions or antibody preparations comprising the specifically glycosylated antibody isoforms. Furthermore, the pharmaceutical and diagnostic uses for these antibodies are provided.Type: GrantFiled: November 7, 2014Date of Patent: March 1, 2016Assignee: F. Hoffmann-La Roche Inc.Inventors: Hansruedi Loetscher, Walter Huber, Diana Schuhbauer, Karl Weyer, Manfred Brockhaus, Bernd Bohrmann, Hans Koll, Andreas Schaubmar, Kurt Lang
-
Publication number: 20150322149Abstract: The present invention relates to blood brain barrier shuttles that bind receptors on the blood brain barrier (R/BBB) and methods of using the same.Type: ApplicationFiled: February 2, 2015Publication date: November 12, 2015Applicant: HOFFMANN-LA ROCHE INC.Inventors: Bernd Bohrmann, Per-Ola Freskgard, Peter Maier, Jens Niewoehner, Alain Tissot-Daguette, Eduard Urich
-
Publication number: 20150175685Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.Type: ApplicationFiled: December 18, 2014Publication date: June 25, 2015Inventors: Fiona Grueninger, Guy Georges, Olaf Mundigl, Michael Schraeml, Bernd Bohrmann, Ulrich Goepfert, Joerg Benz, Hubert Kettenberger
-
Publication number: 20150165022Abstract: The present invention relates to a purified antibody molecule preparation being characterized in that at least one antigen binding site comprises a glycosylated asparagine (Asn) in the variable region of the heavy chain (VH). More specifically, a pharmaceutical and a diagnostic composition comprising said antibody molecule and antibody mixtures are provided which is/are capable of specifically recognizing the ?-A4 peptide/A?4. The present invention relates in particular to a mixture of antibodies comprising one or two glycosylated antigen binding sites with a glycosylated asparagine (Asn) in the variable region of the heavy chain, i.e. mixtures of isoforms of antibodies which comprise a glycosylated Asn in the variable region of the heavy chain (VH). Also disclosed are compositions or antibody preparations comprising the specifically glycosylated antibody isoforms. Furthermore, the pharmaceutical and diagnostic uses for these antibodies are provided.Type: ApplicationFiled: November 7, 2014Publication date: June 18, 2015Inventors: Hansruedi LOETSCHER, Walter HUBER, Diana SCHUHBAUER, Karl WEYER, Manfred BROCKHAUS, Bernd BOHRMANN, Hans KOLL, Andreas SCHAUBMAR, Kurt LANG
-
Patent number: 8906370Abstract: The present invention relates to a purified antibody molecule preparation being characterized in that at least one antigen binding site comprises a glycosylated asparagine (Asn) in the variable region of the heavy chain (VH). More specifically, a pharmaceutical and a diagnostic composition comprising said antibody molecule and antibody mixtures are provided which is/are capable of specifically recognizing the ?-A4 peptide/A?4. The present invention relates in particular to a mixture of antibodies comprising one or two glycosylated antigen binding sites with a glycosylated asparagine (Asn) in the variable region of the heavy chain, i.e. mixtures of isoforms of antibodies which comprise a glycosylated Asn in the variable region of the heavy chain (VH). Also disclosed are compositions or antibody preparations comprising the specifically glycosylated antibody isoforms. Furthermore, the pharmaceutical and diagnostic uses for these antibodies are provided.Type: GrantFiled: December 11, 2006Date of Patent: December 9, 2014Assignee: Hoffmann-La Roche Inc.Inventors: Hansruedi Loetscher, Walter Huber, Diana Schuhbauer, Karl Weyer, Manfred Brockhaus, Bernd Bohrmann, Hans Koll, Andreas Schaubmar, Kurt Lang
-
Patent number: 8609097Abstract: An antibody binding to Tau that is phosphorylated at serine 422 (pS422), which specifically binds to phosphorylated Tau fragment of SEQ ID NO:9 and to Tau pS422, but does not bind to Tau and to phosphorylated MCAK fragment of SEQ ID NO:17. The antibody is useful in the treatment of a Tauopathy.Type: GrantFiled: June 3, 2010Date of Patent: December 17, 2013Assignee: Hoffmann-La Roche Inc.Inventors: Bernd Bohrmann, Ulrich Goepfert, Fiona Grueninger, Walter Huber, Hans-Willi Krell, Valeria Lifke, Olaf Mundigl, Sonja Offner, Laurence Ozmen, Michael Schraeml
-
Publication number: 20130310541Abstract: An antibody binding to Tau that is phosphorylated at serine 422 (pS422), which specifically binds to phosphorylated Tau fragment of SEQ ID NO:9 and to Tau pS422, but does not bind to Tau and to phosphorylated MCAK fragment of SEQ ID NO:17. The antibody is useful in the treatment of a Tauopathy.Type: ApplicationFiled: June 6, 2013Publication date: November 21, 2013Applicant: Hoffmann-La Roche Inc.Inventors: Bernd Bohrmann, Ulrich Goepfert, Fiona Grueninger, Walter Huber, Hans-Willi Krell, Valeria Lifke, Olaf Mundigl, Sonja Offner, Laurence Ozmen, Michael Schraemi
-
Patent number: 8329886Abstract: The present invention relates to antibody molecules capable of specifically recognizing two regions of the ?-A4 peptide, wherein the first region comprises the amino acid sequence AEFRHDSGY as shown in SEQ ID NO: 1 or a fragment thereof and wherein the second region comprises the amino acid sequence VHHQKLVFFAEDVG as shown in SEQ ID NO: 2 or a fragment thereof. Furthermore, nucleic acid molecules encoding the inventive antibody molecules and vectors and hosts comprising said nucleic acid molecules are disclosed. In addition, the present invention provides for compositions, preferably pharmaceutical or diagnostic compositions, comprising the compounds of the invention as well as for specific uses of the antibody molecules, nucleic acid molecules, vectors or hosts of the invention.Type: GrantFiled: May 16, 2012Date of Patent: December 11, 2012Assignees: Hoffman-La Roche Inc., Morphosys AGInventors: Michael Bardroff, Bernd Bohrmann, Manfred Brockhaus, Walter Huber, Titus Kretzschmar, Hansruedi Loetscher, Corinna Löhning, Christer Nordstedt, Christine Rothe
-
Publication number: 20120282176Abstract: Herein is reported a fusion polypeptide comprising i) at least one binding site, e.g. which comprises an antibody heavy chain variable domain and an antibody light chain variable domain, and which binds to an internalizing cell surface receptor, and ii) at least one pharmaceutically active compound, whereby the EC50-value of the binding pair that binds to an internalizing cell surface receptor determined at pH 5.5 is higher than the EC50-value of the same binding pair determined at pH 7.4 and its use for delivering a pharmaceutically active compound across the blood-brain-barrier.Type: ApplicationFiled: April 18, 2012Publication date: November 8, 2012Applicant: Roche Glycart AGInventors: Bernd Bohrmann, Per-Ola Freskgard, Adrian Hugenmatter, Erhard Kopetzki, Ekkehard Moessner, Jens Niewoehner, Hadassah Sumum Sade, Pablo Umaña
-
Publication number: 20120225478Abstract: The present invention relates to antibody molecules capable of specifically recognizing two regions of the ?-A4 peptide, wherein the first region comprises the amino acid sequence AEFRHDSGY as shown in SEQ ID NO: 1 or a fragment thereof and wherein the second region comprises the amino acid sequence VHHQKLVFFAEDVG as shown in SEQ ID NO: 2 or a fragment thereof. Furthermore, nucleic acid molecules encoding the inventive antibody molecules and vectors and hosts comprising said nucleic acid molecules are disclosed. In addition, the present invention provides for compositions, preferably pharmaceutical or diagnostic compositions, comprising the compounds of the invention as well as for specific uses of the antibody molecules, nucleic acid molecules, vectors or hosts of the invention.Type: ApplicationFiled: May 16, 2012Publication date: September 6, 2012Inventors: Michael Bardroff, Bernd Bohrmann, Manfred Brockhaus, Walter Huber, Titus Kretzschmar, Hansruedi Loetscher, Corinna Löhning, Christer Nordstedt, Christine Rothe
-
Patent number: 8216577Abstract: The present invention relates to antibody molecules capable of specifically recognizing two regions of the ?-A4 peptide, wherein the first region comprises the amino acid sequence AEFRHDSGY as shown in SEQ ID NO: 1 or a fragment thereof and wherein the second region comprises the amino acid sequence VHHQKLVFFAEDVG as shown in SEQ ID NO: 2 or a fragment thereof. Furthermore, nucleic acid molecules encoding the inventive antibody molecules and vectors and hosts comprising said nucleic acid molecules are disclosed. In addition, the present invention provides for compositions, preferably pharmaceutical or diagnostic compositions, comprising the compounds of the invention as well as for specific uses of the antibody molecules, nucleic acid molecules, vectors or hosts of the invention.Type: GrantFiled: July 28, 2009Date of Patent: July 10, 2012Assignees: F. Hoffmann-La Roche AG, MorphoSys AGInventors: Michael Bardroff, Bernd Bohrmann, Manfred Brockhaus, Walter Huber, Titus Kretzschmar, Hansruedi Loetscher, Corinna Löhning, Christer Nordstedt, Christine Rothe